ArticleJournal of immunology (Baltimore, Md. : 1950)2012
Type I IFN induced by adenovirus serotypes 28 and 35 has multiple effects on T cell immunogenicity.
Article in Journal of immunology (Baltimore, Md. : 1950), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 57 citations in OpenAlex.
- Safety and Immunogenicity of a rAd35-EnvA Prototype HIV-1 Vaccine in Combination with rAd5-EnvA in Healthy Adults (VRC 012).PloS one · 2016Trial
- Efficacy of intranasal adenovirus vector vaccine is attenuated by type I IFN-induced NK cell activation.Molecular therapy. Advances · 2026Article
- Oncolytic adenovirus serotype 35 mediated tumor growth suppressionJournal for immunotherapy of cancer · 2025Article
- Early spatiotemporal evolution of the immune response elicited by adenovirus serotype 26 vector vaccination in mice.Journal of virology · 2025Article
- Distinct Requirements for CD4European journal of immunology · 2025Article
- Two Novel Adenovirus Vectors Mediated Differential Antibody Responses via Interferon-α and Natural Killer Cells.Microbiology spectrum · 2023Article
- An Oil-Based Adjuvant Improves Immune Responses Induced by Canine Adenovirus-Vectored Vaccine in Mice.Viruses · 2023Article
- Comparative analysis of the impact of 40 adenovirus types on dendritic cell activation and CD8Frontiers in immunology · 2023Article
- Inclusion of a dual signal sequence enhances the immunogenicity of a novel viral vectored vaccine against the capsular group B meningococcus.Cell & bioscience · 2022Article
- The use of adenoviral vectors in gene therapy and vaccine approaches.Genetics and molecular biology · 2022Article
- Natural killer cell immunosuppressive function requires CXCR3-dependent redistribution within lymphoid tissues.The Journal of clinical investigation · 2021Article
- MAIT cell activation augments adenovirus vector vaccine immunogenicity.Science (New York, N.Y.) · 2021Article
- Adenoviral vector-based platforms for developing effective vaccines to combat respiratory viral infections.Clinical & translational immunology · 2021Review
- Factors Which Contribute to the Immunogenicity of Non-replicating Adenoviral Vectored Vaccines.Frontiers in immunology · 2020Review
- Adenovirus vectors in hematopoietic stem cell genome editing.FEBS letters · 2019Review
- In vivo hematopoietic stem cell gene therapy ameliorates murine thalassemia intermedia.The Journal of clinical investigation · 2019Article
- Boosting BCG with proteins or rAd5 does not enhance protection against tuberculosis in rhesus macaques.NPJ vaccines · 2019Article
- Virus-Like-Vaccines against HIV.Vaccines · 2018Review
- Inhibition of type I interferon responses by adenovirus serotype-dependent Gas6 binding.Virology · 2018Article
- Adenoviral vaccine induction of CD8+ T cell memory inflation: Impact of co-infection and infection order.PLoS pathogens · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 7 institutions in 4 countries.
Funding
Abstract
Recombinant adenovirus (rAd) vectors are being investigated as vaccine delivery vehicles in preclinical and clinical studies. rAds constructed from different serotypes differ in receptor usage, tropism, and ability to activate cells, aspects of which likely contribute to their different immunogenicity profiles. In this study, we compared the infectivity and cell stimulatory capacity of recombinant adenovirus serotype 5 (rAd5), recombinant adenovirus serotype 28 (rAd28), and recombinant adenovirus serotype 35 (rAd35) in association with their respective immunogenicity profiles. We found that rAd28 and rAd35 infected and led to the in vitro maturation and activation of both human and mouse dendritic cells more efficiently compared with rAd5. In stark contrast to rAd5, rAd28 and rAd35 induced production of IFN-α and stimulated IFN-related intracellular pathways. However, the in vivo immunogenicity of rAd28 and rAd35 was significantly lower than that of rAd5. Deletion of IFN-α signaling during vaccination with rAd28 and rAd35 vectors increased the magnitude of the insert-specific T cell response to levels induced by vaccination with rAd5 vector. The negative impact of IFN-α signaling on the magnitude of the T cell response could be overcome by increasing the vaccine dose, which was also associated with greater polyfunctionality and a more favorable long-term memory phenotype of the CD8 T cell response in the presence of IFN-α signaling. Taken together, our results demonstrate that rAd-induced IFN-α production has multiple effects on T cell immunogenicity, the understanding of which should be considered in the design of rAd vaccine vectors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.